
    
      62 patients with low cardiovascular risk will be 1:1 randomized to receive either placebo
      (b.i.d.) or 500mg of propionate (b.i.d.). The primary endpoint is the change (delta) in blood
      LDL cholesterol levels after 8 weeks.
    
  